These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 720482)

  • 41. Binding of [125I]-N-(p-aminophenethyl)spiroperidol to the D-2 dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study.
    Agui T; Amlaiky N; Caron MG; Kebabian JW
    Mol Pharmacol; 1988 Feb; 33(2):163-9. PubMed ID: 2963208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dopamine D2 receptor binding in adrenal medulla: characterization using [3H]spiperone.
    Quik M; Bergeron L; Mount H; Philie J
    Biochem Pharmacol; 1987 Nov; 36(21):3707-13. PubMed ID: 2960326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of chronic haloperidol on caudate 3H-spiroperidol binding in lesioned rats.
    Rosenblatt JE; Shore D; Neckers LM; Perlow MJ; Freed WJ; Wyatt RJ
    Eur J Pharmacol; 1979 Dec; 60(4):387-8. PubMed ID: 93551
    [No Abstract]   [Full Text] [Related]  

  • 45. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
    Levant B; Grigoriadis DE; DeSouza EB
    J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of binding sites for [3H]spiroperidol.
    Luedtke RR; Molinoff PB
    Biochem Pharmacol; 1987 Oct; 36(19):3255-64. PubMed ID: 2959288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL; Krstich M; Beart PM
    Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New detection of brain dopamine receptors with (3H)dihydroergocryptine.
    Tittler M; Weinreich P; Seeman P
    Proc Natl Acad Sci U S A; 1977 Sep; 74(9):3750-3. PubMed ID: 410026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigations concerning the cellular origin of dopamine receptors.
    Henn FA; Titeler M; Anderson DJ; May K
    Life Sci; 1978 Aug; 23(6):617-21. PubMed ID: 692285
    [No Abstract]   [Full Text] [Related]  

  • 50. Selective labeling of pre-synaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of post-synaptic sites by 3H-neuroleptics.
    Titeler M; Tedesco JL; Seeman P
    Life Sci; 1978 Aug; 23(6):587-91. PubMed ID: 29197
    [No Abstract]   [Full Text] [Related]  

  • 51. A comparative study of [3H]haloperidol and [3H]spiroperidol binding to receptors on rat cerebral membranes.
    Howlett DR; Nahorski SR
    FEBS Lett; 1978 Mar; 87(1):152-6. PubMed ID: 631328
    [No Abstract]   [Full Text] [Related]  

  • 52. Increased renal neuroleptic binding in spontaneously hypertensive rats.
    Rosenblatt JE; Shore D; Wyatt RJ; Pert CB
    Eur J Pharmacol; 1980 Oct; 67(2-3):317-20. PubMed ID: 6109638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers.
    Seeman P; Westman K; Protiva M; Jílek J; Jain PC; Saxena AK; Anand N; Humber L; Philipp A
    Eur J Pharmacol; 1979 Jun; 56(3):247-51. PubMed ID: 38971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential centrifugation of 3H-apomorphine and 3H-spiroperidol binding sites.
    Titeler M; Seeman P; Henn F
    Eur J Pharmacol; 1978 Oct; 51(4):459-60. PubMed ID: 710514
    [No Abstract]   [Full Text] [Related]  

  • 55. Neuroleptic and dopamine receptors: autoradiographic localization of [3H]spiperone in rat brain.
    Klemm N; Murrin LC; Kuhar MJ
    Brain Res; 1979 Jun; 169(1):1-9. PubMed ID: 455088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guanyl nucleotide interactions with dopaminergic binding sites labeled by [3H]spiroperidol in human caudate and putamen: guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites.
    Andorn AC; Bacon BR; Nguyen-Hunh AT; Parlato SJ; Stitts JA
    Mol Pharmacol; 1988 Feb; 33(2):155-62. PubMed ID: 3340080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil, [3H]S 3608 and [3H]N,n-propylnorapomorphine.
    Hall MD; Jenner P; Marsden CD
    Eur J Pharmacol; 1983 Jan; 87(1):85-94. PubMed ID: 6188621
    [No Abstract]   [Full Text] [Related]  

  • 58. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J; Christensen AV
    J Neural Transm Suppl; 1983; 18():157-64. PubMed ID: 6135740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of sulpiride with human pituitary dopaminergic receptors is sodium dependent.
    Serri O; Marchisio AM; Somma M; Hardy J; Collu R
    Horm Res; 1984; 19(3):153-7. PubMed ID: 6714932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased binding of [3H]apomorphine in caudate membranes after dopamine pretreatment in vitro.
    McManus C; Hartley EJ; Seeman P
    J Pharm Pharmacol; 1978 Jul; 30(7):444-7. PubMed ID: 27612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.